Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499049 | 0.88 | KDM4E (0.60) | KDM4EALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL6530613 | 0.86 | CCR8 (0.60) | KDM4EALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL6498313 | 0.86 | ALDH1A1 (0.65) | KDM4EALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL6507060 | 0.85 | MEN1 (0.70) | KDM4EALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL6497411 | 0.84 | MEN1 (0.63) | KDM4EALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL6509473 | 0.81 | KDM4E (0.65) | KDM4EALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL6496798 | 0.81 | KDM4E (0.59) | KDM4EALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL6495946 | 0.81 | CCR8 (0.64) | KDM4EALDH1A1GAAFAAH | |
| SCHEMBL6497241 | 0.80 | KDM4E (0.58) | KDM4EALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL3037921 | 0.79 | HRH3 (0.65) | HRH3KDM4EALDH1A1SMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | HRH3 801/4885KDM4E 4617/4885ALDH1A1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.